Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit
- PMID: 37197772
- DOI: 10.1136/bmj-2022-071082
Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit
Conflict of interest statement
Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following: AV is a co-inventor of the 4kscore, a commercial test for predicting prostate biopsy outcome. He receives royalties from sales of the test. He owns stock options in Opko, which offers the test. JC has received reimbursement for consultancy from Astra Zeneca, Ferring, Roche, and Janssen; speaker fees from BMS, MSD, Janssen, Astellas, Nucleix and Roche; honoraria for membership of advisory boards for Ferring, Roche, Gilead, Photocure, BMS, QED therapeutics and Janssen; and research funding from Roche. Provenance and peer review: Not commissioned; externally peer reviewed.
Comment in
-
Prostate cancer screening: well intentioned initiatives may use up resources but not improve health outcomes.BMJ. 2023 Jun 21;381:1389. doi: 10.1136/bmj.p1389. BMJ. 2023. PMID: 37343958 No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical